Durvalumab in patients with MRD following surgery and curative intent therapy

• Research type

  Research Study

• Full title

  A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2)

• IRAS ID

  1003392

• Contact name

  Yvonne Summers

• Contact email

  Yvonne.Summers@christie.nhs.uk

• Eudract number

  2020-000612-30

• Research summary

  Summary of results - https://www.trialsummaries.com/Study/StudyDetails?id=11541&tenant=MT_MED_9011
  

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  20/SC/0374

• Date of REC Opinion

  13 Nov 2020

• REC opinion

  Further Information Favourable Opinion